Who
Machelle Sanders
Director
Company insider
Files Form 4 as: Director, Fortrea Holdings; Director, BioCryst Pharmaceuticals; Director, Novan; Director, Radius Health.
In numbers
- Trades disclosed
- 46
- Buys
- 1
- Sells
- 5
- Bought
- $0
- Sold
- $483K
- Companies
- 4
- Companies where not an officer
- 4
- First trade
- 24 Sep 2017
- Last trade
- 3 Aug 2026
- Last filed
- 5 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 3 Aug 2026filed 5 Aug 2026 | FTRE Fortrea HoldingsDiagnostics & Labs | SEC FORM 4 Sold | $175K9,700 at $18.01 | filing |
| 3 Aug 2026filed 5 Aug 2026 | FTRE Fortrea HoldingsDiagnostics & Labs | SEC FORM 4 Sold | $175K9,700 at $18.01 | filing |
| 11 Jun 2026filed 15 Jun 2026 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —15,294 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | BCRX BioCryst Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —33,540 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | BCRX BioCryst Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —33,540 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —15,294 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | FTRE Fortrea HoldingsDiagnostics & Labs | SEC FORM 4 Code M | —38,817 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | FTRE Fortrea Holdingsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code M | —38,817 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | FTRE Fortrea Holdingsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —12,852 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | FTRE Fortrea Holdingsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code M | —38,817 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | FTRE Fortrea Holdingsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —12,852 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | FTRE Fortrea HoldingsDiagnostics & Labs | SEC FORM 4 Code M | —38,817 at $0.00 | filing |
| 13 Nov 2025filed 17 Nov 2025 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $69K9,600 at $7.14 | filing |
| 12 Jun 2025filed 16 Jun 2025 | BCRX BioCryst Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —27,181 at $0.00 | filing |
| 12 Jun 2025filed 16 Jun 2025 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —12,500 at $0.00 | filing |
| 10 Jun 2025filed 12 Jun 2025 | FTRE Fortrea Holdingsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —38,817 at $0.00 | filing |
| 14 May 2025filed 16 May 2025 | FTRE Fortrea Holdingsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code M | —7,282 at $0.00 | filing |
| 14 May 2025filed 16 May 2025 | FTRE Fortrea HoldingsDiagnostics & Labs | SEC FORM 4 Code M | —7,282 at $0.00 | filing |
| 17 Jun 2024filed 17 Jun 2024 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $28K4,689 at $6.00 | filing |
| 12 Jun 2024filed 14 Jun 2024 | BCRX BioCryst Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —49,933 at $0.00 | filing |
News
Critical Review: Champions Oncology (NASDAQ:CSBR) and Fortrea (NASDAQ:FTRE)FTRE · dailypolitical.com · 18 Oct 2026Reviewing MindWalk (NASDAQ:HYFT) & Fortrea (NASDAQ:FTRE)FTRE · tickerreport.com · 12 Oct 2026
0 headlines in the last 90 days name Machelle Sanders; 2 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.